KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 81 filers reported holding KEROS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,873,662 | -46.9% | 341,081 | -33.1% | 0.93% | -53.1% |
Q2 2023 | $20,470,143 | -36.5% | 509,461 | -32.5% | 1.98% | -19.8% |
Q1 2023 | $32,243,581 | -19.5% | 755,119 | -9.5% | 2.47% | -4.8% |
Q4 2022 | $40,048,344 | +19.9% | 833,993 | -6.0% | 2.60% | +20.1% |
Q3 2022 | $33,391,000 | +26.7% | 887,592 | -6.9% | 2.16% | +63.6% |
Q2 2022 | $26,354,000 | -43.6% | 953,801 | +11.1% | 1.32% | -36.1% |
Q1 2022 | $46,698,000 | -4.6% | 858,730 | +2.7% | 2.07% | +20.0% |
Q4 2021 | $48,938,000 | +62.7% | 836,398 | +10.0% | 1.72% | +81.6% |
Q3 2021 | $30,081,000 | +18.3% | 760,383 | +27.0% | 0.95% | +31.1% |
Q2 2021 | $25,434,000 | -10.2% | 598,880 | +30.1% | 0.72% | -12.7% |
Q1 2021 | $28,336,000 | -24.8% | 460,372 | -13.9% | 0.83% | -29.1% |
Q4 2020 | $37,705,000 | +253.1% | 534,514 | +93.1% | 1.17% | +257.2% |
Q3 2020 | $10,677,000 | +3.5% | 276,827 | +0.7% | 0.33% | +5.1% |
Q2 2020 | $10,315,000 | – | 275,000 | – | 0.31% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 321,300 | $12,087,000 | 4.99% |
First Light Asset Management, LLC | 598,213 | $22,505,000 | 2.28% |
Nantahala Capital Management | 845,692 | $31,815,000 | 2.06% |
CHI Advisors LLC | 200,229 | $7,533,000 | 2.03% |
Fairmount Funds Management LLC | 272,498 | $10,251,000 | 1.80% |
Altium Capital Management LP | 88,000 | $3,311,000 | 1.21% |
Orbimed Advisors | 1,679,417 | $63,180,000 | 1.17% |
SPHERA FUNDS MANAGEMENT LTD. | 206,819 | $7,781,000 | 1.08% |
Parkman Healthcare Partners LLC | 99,927 | $3,759,000 | 1.07% |
Soleus Capital Management, L.P. | 146,000 | $5,493,000 | 0.75% |